A single arm phase II study to individualize dasatinib dosing based on trough levels and molecular response to maintain efficacy whilst minimising toxicity (CML12)

Dataset includes: Data for 80 patients over 60 with newly diagnosed CML, using desatinib and monitoring lung function Diagnostic data, treatment data, outcome data Cancer Australia demographic data -Year of birth -Aboriginal or Torres Strait Islander status (or Ethnicity)